NotablePrimary endpoints: details revised at 2 of 2 entriesShow 4 more changesShow less
Trial sites expanded: 155 → 165 locations
Interventions: Investigator's Choice of Therapy (Drug), ZL-1310 (Drug) to Investigator's Choice of Therapy (Drug), ZL-1310 (Drug)
Eligibility criteria expanded, about 20 words
Secondary endpoints: details revised at 9 of 9 entries
MinorRe-verified, no change to tracked fieldsv12
MinorTrial sites expanded: 111 → 155 locationsv11
MinorTrial sites expanded: 76 → 111 locations
Secondary endpoints: details revised at 9 of 9 entries
v10
MinorTrial sites expanded: 66 → 76 locations
Site details revised at 5 of 76 sites
v9
MinorStudy sites: 66 to 76v8
MinorTrial sites expanded: 56 → 66 locationsv7
MinorTrial sites expanded: 34 → 56 locationsv6
MinorTrial sites expanded: 14 → 34 locationsv5
MinorStudy sites: 9 to 14v4
MinorStudy sites: 5 to 9
Study title expanded, about 1 word
v3
NotableTrial status: Not Yet Recruiting to Recruitingv2Show 8 more changesShow less
Enrollment target: 665 to 480
Study sites: 0 to 5
Primary completion date: Nov 30, 2028 to Jun 30, 2028
Study completion date: May 31, 2029 to Nov 30, 2028
Interventions: Investigator's Choice of Therapy (Drug), ZL-1310 Dose Level 1 (Drug), ZL-1310 Dose Level 2 (Drug) to Investigator's Choice of Therapy (Drug), ZL-1310 (Drug)
Eligibility criteria shortened, about 8 words
Secondary endpoints: details revised at 9 of 9 entries
Study arms: 3 to 2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.